Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Patient-reported outcomes predict high readmission rates among patients with cardiac diagnoses. Findings from the DenHeart study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Women with coronary microvascular dysfunction and no obstructive coronary artery disease have reduced exercise capacity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Longitudinal study of electrical, functional and structural remodelling in an equine model of atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Supraventricular ectopic complexes (SVEC) are known risk factors of recurrent atrial fibrillation (AF). However, the impact of SVEC in different age groups is unknown. We aimed to investigate the risk of AF recurrence with higher SVEC burden in patients ±57years, respectively, after treatment with antiarrhythmic medication (AAD) or catheter ablation (CA).

METHODS: In total, 260 patients with LVEF >40% and age ≤70 years were randomized to AAD (N=132) or CA (N=128) as first-line treatment for paroxysmal AF. All patients underwent 7-day Holter monitoring at baseline, and after 3, 6, 12, 18 and 24months and were categorized according to median age ±57years. We used multivariate Cox regression analyses and we defined high SVEC burden at 3months of follow-up as the upper 75th percentile >195SVEC/day. AF recurrence was defined as AF ≥1min, AF-related cardioversion or hospitalization.

RESULTS: Age >57years were significantly associated with higher AF recurrence rate after CA (58% vs 36%, p=0.02). After CA, we observed a higher SVEC burden during follow-up in patients >57years which was not observed in the younger age group treated with CA (p=0.006). High SVEC burden at 3months after CA was associated with AF recurrence in older patients but not in younger patients (>57years: HR 3.4 [1.4-7.9], p=0.005). We did not find any age-related differences after AAD.

CONCLUSION: We found that younger and older patients respond differently to CA and that SVEC burden was only associated with AF recurrence in older patients.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cardiology
Vol/bind250
Sider (fra-til)122-127
ISSN0167-5273
DOI
StatusUdgivet - jan. 2018

ID: 51951890